Autres langues Amarantus BioScience Holdings, Inc.

Actions

AMBS

US02300U2050

Marché Fermé - OTC Markets Autres places de cotation 21:51:04 15/05/2024			Varia. 5j.	Varia. 1 janv.
0,0001 ^USD	0,00%		0,00%	-80,00%

2022

Mise à jour sectorielle : Les valeurs financières ajoutent encore aux baisses de mercredi

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Sector Update: Financial Stocks Still Adding to Wednesday Declines	30/03/22
Amarantus BioScience : Notification of Late Filing	18/11/21
Amarantus BioScience : Todos Medical Completes Acquisition of Breakthrough Diagnostics, Gains Full Rights to the Alzheimer’s Blood Diagnostic LymPro™ Test from Amarantus	28/07/20
Todos Medical Ltd. (OTCPK:TOMD.F) completed the acquisition of remaining 80.01% stake in Breakthrough Diagnostics Inc. from Amarantus BioScience Holdings, Inc.	28/07/20
Emerald Organic Products : Restructures Joint Venture Agreement With Todos Medical by Entering Joint Collaboration Agreement	08/05/20
Amarantus BioScience : Todos Medical and 3DMed Enter Into Coronavirus (COVID-19) and Influenza A/B Testing Kit Distribution Agreement in US and Israel	17/03/20
Amarantus BioScience : Announces Subsidiary MANF Therapeutics Enters Into Material Transfer Agreement with Dyadic International	06/02/20
Amarantus Releases Letter to Shareholders	04/02/20
Amarantus Acquires Majority Interest in CBD Wellness Company Hempori	30/01/20
Amarantus BioScience Holdings, Inc. acquired majority interest in Hempori, Inc. for $0.38 million.	30/01/20
Emerald Organic Products : Amarantus Completes Sublicense of ESS, MANF and PhenoGuard to Emerald Organic Products	02/01/20
Amarantus Completes Sublicense of ESS, MANF and Phenoguard to Emerald Organic Products	02/01/20
Amarantus to Present at 12th Annual LD Micro Main Event	09/12/19
Amarantus Subsidiary Elto Pharma Receives Notice of Allowance Covering Use of Eltoprazine Combined with CBD to Treat Parkinson’s Disease	04/12/19
Amarantus Announces Issuance of Chinese Patent Covering the Use of MANF and CDNF in Retinal Disorders for Subsidiary MANF Therapeutics	21/11/19
Amarantus Announces Issuance of Chinese Patent Covering the Use of MANF and CDNF in Retinal Disorders for Subsidiary Manf Therapeutics	21/11/19
Amarantus Provides Recapitalization Update to Shareholders	18/11/19
Amarantus Enters Into Agreement to License Diverse Therapeutics Portfolio to CBD-focused Emerald Organic Products	24/10/19
Amarantus Bioscience Holdings, Inc. Enters into Agreement to License Diverse Therapeutics Portfolio to CBD-Focused Emerald Organic Products with Emerald Organic Growth, Inc	24/10/19
Coeptis Pharmaceuticals, Inc. terminated the acquisition of Elto Pharma, Inc. from PsychoGenics Inc. and Amarantus BioScience Holdings, Inc..	24/10/19

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Amarantus BioScience Holdings, Inc.

Actions

AMBS

US02300U2050

Autres langues

Filtres